{"title":"Successful Treatment of Pediatric Generalized Pustular Psoriasis with Secukinumab.","authors":"Keyi Yu, Huaye Bao, Xingang Wu","doi":"10.2147/CCID.S493665","DOIUrl":null,"url":null,"abstract":"<p><p>Generalized Pustular Psoriasis (GPP) is a rare, severe, life-threatening form of psoriasis and often resistant to conventional systemic therapy. It can be induced by deficiency of interleukin (IL)-36 receptor antagonist. Treatment of patients with GPP is often difficult, and there is no consensus on the best options available to date. However, multiple biologics approved for use in plaque-type psoriasis have also been used in GPP. Here, we report a 6-year-old boy with GPP who was misdiagnosed with AGEP and was treated with corticosteroids but did not respond well. He showed significant improvement following secukinumab treatment. Our case report indicates that IL-17A inhibition as a promising therapeutic option for pediatric GPP without combination with other systemic agents.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"18 ","pages":"105-108"},"PeriodicalIF":1.9000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11745051/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical, Cosmetic and Investigational Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/CCID.S493665","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Generalized Pustular Psoriasis (GPP) is a rare, severe, life-threatening form of psoriasis and often resistant to conventional systemic therapy. It can be induced by deficiency of interleukin (IL)-36 receptor antagonist. Treatment of patients with GPP is often difficult, and there is no consensus on the best options available to date. However, multiple biologics approved for use in plaque-type psoriasis have also been used in GPP. Here, we report a 6-year-old boy with GPP who was misdiagnosed with AGEP and was treated with corticosteroids but did not respond well. He showed significant improvement following secukinumab treatment. Our case report indicates that IL-17A inhibition as a promising therapeutic option for pediatric GPP without combination with other systemic agents.
期刊介绍:
Clinical, Cosmetic and Investigational Dermatology is an international, peer-reviewed, open access journal that focuses on the latest clinical and experimental research in all aspects of skin disease and cosmetic interventions. Normal and pathological processes in skin development and aging, their modification and treatment, as well as basic research into histology of dermal and dermal structures that provide clinical insights and potential treatment options are key topics for the journal.
Patient satisfaction, preference, quality of life, compliance, persistence and their role in developing new management options to optimize outcomes for target conditions constitute major areas of interest.
The journal is characterized by the rapid reporting of clinical studies, reviews and original research in skin research and skin care.
All areas of dermatology will be covered; contributions will be welcomed from all clinicians and basic science researchers globally.